title: [Natural history of localized prostate cancer. Preliminary data on progression and mortality].
abstract: OBJECTIVE
  To address the effect of therapy options and other factors on the natural history of localized prostate cancer (PCa).
  
  
  METHODS
  Men with diagnosed clinically localized PCa who underwent radical prostatectomy (RP), radiotherapy (RT) or watchful waiting (WW). Rates of biochemical progression (BQP) and clinical progression (CLP) were calculated. The effects of therapy, initial PSA, presence of palpable tumor and Gleason score were assessed with Kaplan-Meier analysis and log-rank test. Similar methods were used to study overall and disease-specific survival.
  
  
  RESULTS
  A total of 228 patients were studied (135 underwent RP, 46 RT, and 47 WW). Median followup time was 2.5 years. Forty patients presented with BQP. The probability of being free from BQP after 2 and 5 years was 76.8% and 57.9% respectively for the whole population, 70.9% and 57.6% for RP patients, 100% and 100% for RT, and 87.1% and 47.2% for WW (p = 0.031). Nineteen patients presented with CLP, with no significant differences with regard to therapy option. A poorly differentiated Gleason score favoured the probability of presenting with CLP (p = 0.022) and shift to metastatic disease (p < 0.001). No cancer-specific mortality was recorded in the studied population.
  
  
  CONCLUSIONS
  Short and medium-term prognosis is excellent for localized prostate cancer in terms of survival. Nevertheless, some patients show a higher risk of progressing to metastatic disease (poorly differentiated Gleason score).
authors.affiliation: Servicio de Urología, Hospital Universitario de Getafe, Madrid. marcoslujan@terra.es
authors.forename: M
authors.initials: M
authors.lastname: Luján Galán
authors.forename: A
authors.initials: A
authors.lastname: Paéz Borda
authors.forename: M A
authors.initials: MA
authors.lastname: Cabeza Rodríguez
authors.forename: G M
authors.initials: GM
authors.lastname: Espinales Castro
authors.forename: I
authors.initials: I
authors.lastname: Romero Cagigal
authors.forename: C A
authors.initials: CA
authors.lastname: Escalera Almendros
authors.forename: A
authors.initials: A
authors.lastname: Berenguer Sánchez
mesh_terms: D000328:Adult; D000368:Aged; D018450:Disease Progression; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000401:mortality* / Q000628:therapy*